Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement

Thrombosis Research

Volumn 134, Issue 5, 2014, Pages 1074-1080

  Joly, Bérangère ^a   Stepanian, Alain ^b   Hajage, David ^b   Thouzeau, Sandrine ^a,c   Capdenat, Sophie ^a   Coppo, Paul ^c   Veyradier, Agnès ^a,c  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Adamts13; ADAMTS13 activity; Chr VWF73; FRETS VWF73; Thrombotic thrombocytopenic purpura

Indexed keywords

UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR 73; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; PEPTIDE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ELISA KIT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUOROMETRY; FOLLOW UP; HUMAN; LIMIT OF DETECTION; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; CHEMISTRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; METABOLISM; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REPRODUCIBILITY;

ADAM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LIMIT OF DETECTION; PEPTIDES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REPRODUCIBILITY OF RESULTS; VON WILLEBRAND FACTOR;

EID: 84927650009     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.09.006     Document Type: Article

References (23)

1. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112:11-8.
2. Furlan M, Robles R, Galbusera M., Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-84.
3. Levy GG, Nichols WC, Lian E.C., Foroud T., McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413:488-94.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585-94.
5. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C., et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106:1262-7.
6. Peyvandi F, Lavoretano S, Palla R., Feys HB, Vanhoorelbeke K, Battaglioli T, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-9.
7. Veyradier A, Obert B, Houllier A., Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98:1765-72.
8. Lattuada A, Rossi E, Calzarossa C., Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88:1029-34.
9. Hie M, Galicier L, Provot F., Presne C, Poullin P, Bonmarchand G., et al. French Throm-botic Micronagiopathies Reference center. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 2014; 124:204-10.
10. Peyvandi F, Palla R, Lotta L.A., Mackie I., Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8:631-40.
11. Studt J-D, Böhm M, Budde U., Girma J-P, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1:1882-7.
12. Tripodi A, Chantarangkul V, Böhm M, Budde U., Dong J-F, Friedman KD, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2:1601-9.
13. Mahdian R, Rayes J, Girma J-P, Houllier A, Obert B., Meyer D, et al. Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples. Thromb Haemost 2006; 95:1049-51.
14. Kokame K, Nobe Y, Kokubo Y., Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129:93-100.
15. Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013; 11:11-23.
16. Muia J, Gao W, Haberichter S.L., Dolatshahi L., Westfield LA, Covill SC, et al. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 2013; 11:1511-8.
17. Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiol-ogy and therapeutic strategies. Hematology Am Soc Hematol Educ Program 2013; 2013:292-9.
18. Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia 1998; 4(Suppl. 3):15-24.
19. Gerritsen HE, Turecek PL, Schwarz H.P., Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82:1386-9.
20. Mackie I, Langley K, Chitolie A., Liesner R, Scully M, Machin S., et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost 2013; 109:488-96.
21. Thouzeau S, Capdenat S, Stépanian A, Coppo P., Veyradier A. Evaluation of a commercial assay for ADAMTS13 activity measurement. Thromb Haemost 2013; 110: 852-3.
22. Moatti-Cohen M, Garrec C, Wolf M., Boisseau P, Galicier L, Azoulay E., et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119:5888-97.
23. Mancini I, Valsecchi C, Lotta L.A., Deforche L., Pontiggia S, Bajetta M, et al. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb Haemost 2014:112-5.